Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Subscribe To Our Newsletter & Stay Updated
